eet 1	of 1		DIPE				
INFORMATION DISCLOSURE CITATION		APR 2 1 2004 :		SERIAL NO.	SERIAL NO.		
				09/763,955			
		APPLICANT	's audio				
		<b>VON BORSTEL</b>	RADEMARKS				
(Use several sheets if necessary)		FILING DATE		TC/A.U.			
		February 28, 200	1	1623			
		· · · · · · · · · · · · · · · · · · ·					
CAMINER		U.S. PATENT I	NAME	CLASS	SUBCI ASS	FILING DA	
NITIAL	DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	IF AFFRORM	
					<del> </del>	<u> </u>	
	<u> </u>	FOREIGN PATEN	T DOCUMENTS	<u> </u>	1		
	DOCUMENT	DATE	COUNTRY	CLASS	SUBCLASS	TRANSLATI YES N	
				1			
		MENTS (including Authome of Megaloblastic Anem				egradation":	
PL	Purine and Pyrimidine M	letabolism in Man VII, Part	B; pp. 345-348 (1991	l).			
1		ome of Seizures and Pervasi Purine and Pyrimidine Meta			vith Excessiv	e Cellular	
$T^{-}$	Ferrante, R.J., et al; "Neu	roprotective Effects of Creating 20(12), pp 4389-4397, June	itine in a Transgenic I		Huntington's	Disease"; The	
		ne Prevents Nigrostriatal Do	paminergic Neurodeg	generation in the I	MPTP Mode	l of Parkinson	
			signal Triple in Doubling	on's Disease": An	anion And	emy of	
BL	Disease"; PNAS, Vol. 98.	roprotective Agents for Cli	nical Trials in Parkins		енсан Асаа		
PL	Disease"; PNAS, Vol. 98. Ravina, B.M., et al; "Neu	roprotective Agents for Cli	nicai Triais in Parkins	on's Disease, An	erican Acaa		

Examiner: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to application.